InDex Pharmaceuticals Holding AB

InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options.

The company’s foremost asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe active ulcerative colitis – a debilitating, chronic inflammation of the large intestine. InDex has also developed a platform of patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in treatment of various immunological diseases. InDex is based in Stockholm, Sweden. The company’s shares are traded on Nasdaq First North Stockholm.

Kategorier: Pharma

Gå till InDex Pharmaceuticals Holding ABs hemsida